215 First Street, 3rd Floor
About Relay Therapeutics
Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
CSO and Co-Founder: Mark Murcko, Ph.D.
CEO: Sanjiv Patel
VP, Corporate Development and Strategy: Deborah Palestrant
22 articles with Relay Therapeutics
Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, today announced that Sanjiv K. Patel, M.A., M.D., MBA, president and chief executive officer, will present a company overview at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 at 11:30 a.m. ET.
2/8/2019In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.
Prior to joining Relay Therapeutics, Dr. Pryce worked in Corporate Strategy at Shire Pharmaceuticals.
Relay Therapeutics announced that Sanjiv Patel, M.D., president and chief executive officer, is scheduled to present an overview of the company’s business and scientific objectives at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 at 11:00 a.m. PT (2:00 p.m. ET).
12/28/2018As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
The latest financing round raises the amount of funding the company has received to more than $500 million.
Proceeds to Support Scaling and Advancement of Therapeutics Pipeline & Enhancement of Computational and Experimental Platform
Relay Therapeutics Strengthens R&D Leadership Team with Key Additions in Chemistry and Pharmaceutical Development
Relay Therapeutics, a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced the appointments of Mary Mader, Ph.D., as vice president of chemistry, and Mahesh Padval, Ph.D., as senior vice president of pharmaceutical drug development.
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
Relay Therapeutics is committed to integrating talented people across disciplines to create new medicines for patients
Relay Therapeutics announced the appointment of Steven Kafka, Ph.D., to its board of directors.
Andrew Huberman, researcher in the Stanford University Department of Neurobiology, is taking an unusual approach to investigating possible treatments for glaucoma and anxiety disorders—virtual reality.
Advances in data storage and processing, as well as biomarker identification, has led to cutting-edge breakthroughs in clinical and research imaging technology. Here’s a look at just a few of these stories.
Relay Therapeutics, a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced the appointments of Don Bergstrom, M.D., Ph.D. as Executive Vice President, Head of Research and Development, Brian Adams as General Counsel, and Tom Catinazzo as Vice President of Finance.
Relay Therapeutics, a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at Cowen and Company’s 38th Annual Health Care Conference.
Based in Cambridge, MA and founded in February 2016, Relay Therapeutics focuses on developing therapeutics based on protein motion.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
The round was led by BVF Partners, with new investors GV, Casdin Capital, EcoR1 Capital and Section 32.
O’Brien joins Relay Therapeutics with significant strategic human resources experience in the life sciences industry.
Relay Therapeutics Names Deborah Palestrant, Ph.D., Vice President Of Corporate Development And Strategy